Compare VLTO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VLTO | ILMN |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | VLTO | ILMN |
|---|---|---|
| Price | $100.43 | $135.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 16 |
| Target Price | $113.25 | ★ $116.19 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 02-03-2026 | 02-05-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | ★ 12.64 | N/A |
| EPS | 3.65 | ★ 4.46 |
| Revenue | ★ $5,452,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $5.83 | $2.08 |
| P/E Ratio | ★ $27.56 | $30.22 |
| Revenue Growth | ★ 6.15 | N/A |
| 52 Week Low | $83.87 | $68.70 |
| 52 Week High | $110.11 | $153.06 |
| Indicator | VLTO | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 64.21 |
| Support Level | $98.42 | $129.29 |
| Resistance Level | $101.75 | $137.09 |
| Average True Range (ATR) | 1.72 | 3.84 |
| MACD | 0.12 | -0.64 |
| Stochastic Oscillator | 53.28 | 82.09 |
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.